Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
Authors
Bröckelmann, PZagadailov, E
Corman, S
Chirikov, V
Johnson, C
Macahilig, C
Seal, B
Dalal, M
Illidge, Timothy M
Affiliation
Department I of Internal Medicine and German Hodgkin Study Group (GHSG), University Hospital of Cologne, CologneIssue Date
2017-09-26
Metadata
Show full item recordAbstract
Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate licensed for the treatment of relapsed/refractory Hodgkin lymphoma (rrHL) following autologous stem cell transplant (ASCT) or at least two prior therapies when ASCT or multiagent chemotherapy is not an option. The objective of this study was to describe real-world outcomes with BV in patients with rrHL considered ASCT ineligible or who refuse ASCT.Citation
Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study. 2017, Eur J HaematolJournal
European Journal of HaematologyDOI
10.1111/ejh.12973PubMed ID
28949403Type
ArticleLanguage
enDescription
Lymphoma Research TeamISSN
1600-0609ae974a485f413a2113503eed53cd6c53
10.1111/ejh.12973